Quantcast
Last updated on April 21, 2014 at 1:20 EDT

Latest Gynecologic oncology Stories

2010-09-02 06:30:00

TORONTO, Sept. 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that the Gynecologic Oncology Group (GOG) intends to conduct a randomized Phase II trial of weekly paclitaxel versus weekly paclitaxel with REOLYSIN(R) in patients with persistent or recurrent, ovarian, fallopian tube or primary peritoneal cancer (GOG186H). The study has been approved and will be sponsored by the Cancer Therapy Evaluation Program, Division of Cancer...

2010-08-04 11:51:00

IRVINE, Calif., Aug. 4 /PRNewswire/ -- OvaGene Oncology Inc., a biotechnology company specializing in the development and commercialization of personalized DNA-based diagnostics for gynecologic cancer, is pleased to announce their partnership with The Gynecologic Oncology Group (GOG) through the Industry Collaboration Team (ICT) program. By becoming a member of the ICT, OvaGene Oncology demonstrates its commitment to building a strong partnership with the GOG research groups, namely...

2010-07-12 13:27:00

IRVINE, Calif., July 12 /PRNewswire/ -- OvaGene Oncology Inc., a biotechnology company specializing in the development and commercialization of personalized DNA-based diagnostics for gynecologic cancer, announced today that it has completed license agreements with key Norwegian cancer researchers. The agreements allow OvaGene to validate two new promising genomic technologies with the intention of developing these into clinical laboratory tests. Validation studies and the subsequent...

2010-07-06 13:15:02

Discovery provides new hope to cancer patients with few treatment options Investigators at the Translational Genomics Research Institute (TGen) have discovered a way that may help ovarian cancer patients who no longer respond to conventional chemotherapy. A scientific paper that will be published in the September issue of the journal Gynecologic Oncology describes how the inhibition of a protein, CHEK1, may be an effective element to incorporate into therapies for women with ovarian cancer....

2010-06-22 12:22:00

IRVINE, Calif., June 22 /PRNewswire/ -- OvaGene Oncology Inc., a biotechnology company specializing in the development and commercialization of personalized DNA-based diagnostics for gynecologic cancer, announced today the opening of its new clinical and research laboratory in Irvine, California. This state-of-the-art facility will serve as the central headquarters for operations, research, and molecular clinical lab testing. The opening of the laboratory is an important first step for...

2010-06-22 11:00:00

New Survey Offers Data Updates into Practice Patterns, Compensation and Demographics of Gynecologic Oncologists and the State of Women's Cancer Care CHICAGO, June 22 /PRNewswire-USNewswire/ -- The Society of Gynecologic Oncologists (SGO), the country's leading organization of board certified women's cancer specialists, is now offering the results of its member-based, demographic and practice survey: "Gynecologic Oncology 2010: State of the Subspecialty." The comprehensive survey takes an...

2010-06-08 11:08:00

Further initiatives are recommended to promote uptake of prophylactic HPV vaccination that target high-risk women before existing disparities widen CHICAGO, June 8 /PRNewswire-USNewswire/ -- The Society of Gynecologic Oncologists (SGO) has published its third in a series of four papers on a variety of cervical cancer issues and topics featured at "The Future Strategies for Cervical Cancer Prevention: What Do We Need to Do Now to Prepare" Forum. The paper, entitled "Can the Barriers to HPV...

2010-06-07 14:34:00

HACKENSACK, N.J., June 7 /PRNewswire/ -- The John Theurer Cancer Center at Hackensack University Medical Center announced today the addition of Ami Vaidya, M.D. to the division of gynecologic oncology. Dr. Vaidya is dual-board certified in gynecologic-oncology and obstetrics-gynecology. She brings a world-class education and more than seven years of gynecology experience to the cancer center. "We are thrilled to have Dr. Vaidya join our expert gynecologic oncology team," said Andrew L....

2010-06-06 11:30:00

CHICAGO, June 6 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced positive results from a Phase 2 clinical study evaluating single-agent NKTR-102 in women with platinum-resistant/refractory ovarian cancer. A total of 68 patients were enrolled with platinum-resistant disease, half of whom were platinum refractory. All 68 patients were evaluable for the primary endpoint of objective response rate using Gynecologic Cancer InterGroup (GCIG) criteria, which is a...

2010-05-18 11:00:00

Updated Survey Data Offers Insights into Practice Patterns, Compensation and Demographics of Gynecologic Oncologists and the State of Women's Cancer Care CHICAGO, May 18 /PRNewswire-USNewswire/ -- The Society of Gynecologic Oncologists (SGO), the country's leading organization of board certified women's cancer specialists, has just released the results of a member-based, demographic and practice survey: "Gynecologic Oncology 2010: State of the Subspecialty." The comprehensive survey takes...